Live Markets  BS Home News Now Markets & Investing Companies & Industry  Portfolio SAT 21 NOV, 2009 09:58 PM FEEDBACK 
  Live Markets* > Company Details
Get Quote Search
Stock Quote Sun Pharmaceuticals Industries Ltd
BSE: Rs 1437.00   22.05 (1.56%)
November,20 03:59
NSE: Rs 1,436.8   20.7 (1.46%)
November,20 03:59
Sensex
BSENSE
 
Sun Pharmaceuticals Industries Ltd
Sector Gainers
Sector Losers
CompanyLast (Rs)Gain (%)
Titan BioTech25.7010.30
Inwinex Pharma.4.534.86
Saamya Biotech6.704.85
Natco Pharma114.204.48
Mangalam Drugs11.854.22
Welcure Drugs2.673.09
Bal Pharma26.252.94
Glenmark Pharma.254.102.94
(Source: BSE)
 more  
 Financials Results (Quarterly)
 Particulars (Rs lakh) Sep-09 Jun-09
 Sale6641347675
 Other Income-62721466
 Total expenses3378331569
 Net profit2030612151
 Equity1035610356
 more  
(Source: BSE)
  Broker Calls
Report Name Broker Name Reco Price View
Sun Pharma Angel Broking Neutral 1404
Sun Pharma Angel Broking Neutral 1172
Sun Pharma Angel Broking Neutral 1140
Sun Pharma Macquarie Overweight 1217
Sun Pharma Angel Broking Buy 1219
Sun Pharma Angel Broking Buy 1047
Sun Pharma Angel Broking Neutral 1410
Sun Pharma Religare Buy 1403
Sun Pharma Religare Buy 1403
Sun Pharma Angel Broking Neutral 1447
  Returns (%) more 
Particulars BSE(%) NSE(%) 
One month7.847.82
Six months13.1913.30
One year32.9332.72
(Source: BSE)
 
BSE: 524715 | NSE: SUNPHARMA
 BSENSE
Open 1415.00 1409.00
Day High 1447.90 1444.90
Day Low 1396.00 1395.00
Previous Close 1414.95 1416.10
52-Week high 1600.00 1599.00
52-Week low 953.00 954.00
P/E 20.94 20.94
Market Cap (Rs cr) 29763.14 29759
Volume 15682.00 214321.00
 Peer Group
Company Last (Rs) Mkt Cap (Rs cr)
Ranbaxy Labs. 422.45 17758
Cipla 308.95 24013
Biocon 267.90 5358
Cadila Health. 570.85 7792
Piramal Health 400.85 8378
Glenmark Pharma. 254.10 6368
(Source: BSE)
 Company Profile - Sun Pharma.Inds.
Profile
Chairman & Managing Director: Dilip S Shanghvi
Email: corpcomm@sunpharma.com
Site Url: www.sunpharma.com
Company Address
SPARC
Tandalija
Vadodara
Phone: 91-265-5515500/600/700
Fax: 91-265-235487
 
  Sun Pharma.Inds. News more 
Caraco looking at shifting production to India
Sun Pharma accuses Taro director of misusing funds
Sun Pharma net profit dips 11.5%
'We are not a topline-driven company'
Sun Pharma rises 2.3% on nod for generic drug
Taro files new lawsuit against Sun Pharma
Sun, Caraco to file 30 marketing applications for generics
  Performance & Analysis more 
ParticularsBSENSE
EPS (Trailing 12 mnths,Rs)48.5748.57
Free Float (%)36.2936.29
FII holding 19.0419.04
ROCE(%)25.0925.09
Face Value (in Rs) 5.00
  Shareholding Pattern more 
ParticularsMar-08Dec-07
Indian promoters63.6565.49
Foreign promoters--
Acting person--
Other promoters0.060.06
MFs/UTI3.423.29
Banks/FIs1.541.59
FIIs19.1418.46
Public corporate bodies3.753.97
Indian public5.976.22
NRIs/OCBs--
Others2.480.92
No of shares207116391201446615
(Source: BSE)
  
Quick Links
Market News Commodities News
Top Gainers Top Losers
52 Week High 52 Week Low
The Smart Investor Broker calls
BSE Notices IPO
 
Stock Name A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
 
Business Standard Network:  Business Standard.com | BSmotoring.com | BShindi.com | E-paper | Portfolios
ABOUT US PARTNER WITH US JOBS@BS ADVERTISE WITH US TERMS & CONDITIONS SITE MAP CONTACT US
Business Standard Ltd. Copyright & Disclaimer feedback@business-standard.com
This site is best viewed with Internet Explorer 6.0 or higher; Firefox 2.0 or higher at a minimum screen resolution of 1024x768
* Stock quotes delayed by 10 minutes or more. All information provided is on "as is" basis and for information purposes only. Kindly consult your financial advisor or stock broker to verify the accuracy and recency of all the information prior to taking any investment decision. While due diligence is done and care taken prior to uploading the stock price data, neither Business Standard Limited, www.business-standard.com nor any independent service provider is/are liable for any information errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.